35. Relapsing Clostridium difficile Infection (CDI): When Standard Medical Therapy Fails
Thursday, October 3, 2013: 10:30 AM-12:00 PM
Room: The Moscone Center: 104 (Gateway Ballroom)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the fecal microbiome in health and how the altered microbiome sets the stage for relapsing Clostridium difficile infection (CDI)
  • outline the various approaches to administer fecal microbiome therapy (FMT) and how to get paid for providing FMT
  • discuss alternative treatment strategies using stool substitution therapy to resolve relapsing CDI

Target Audience: scientists, researchers, public health practitioners, pharmacists, nurses, microbiologists, members-in-training, lab personnel, investigators, infectious diseases physicians, infectious diseases pediatricians, infection preventionists, hospital epidemiologists, hospital administrators, HIV specialists, HIV clinicians, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID

Moderators:  Johan S Bakken, MD, PhD, FIDSA, St. Luke ID Associates and Daniel Mcquillen, MD, FIDSA, Lahey Hospital & Medical Center

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-116-L01-P


J. S. Bakken, Rebiotix Inc.: Scientific Advisor, Consulting fee

D. Mcquillen, None

V. B. Young, Pfizer ASPIRE: Grant Investigator, Research grant
Viropharma: Scientific Advisor, travel reimbursement

J. S. Bakken, Rebiotix Inc.: Scientific Advisor, Consulting fee

E. Petrof, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.